Skip to main content
. 2024 Apr 12;8(15):4223–4233. doi: 10.1182/bloodadvances.2024012798

Table 5.

Cause of death

De novo AML (n = 393) sAML (n = 91) Overall (N = 484)
Original disease 227 (59.3%) 36 (40.9%) 263 (55.8%)
Infection 75 (19.6%) 23 (26.1%) 98 (20.8%)
GVHD 36 (9.4%) 8 (9.1%) 44 (9.3%)
Non-HSCT related 14 (3.7%) 3 (3.4%) 17 (3.6%)
Other transplant related 8 (2.1%) 1 (1.1%) 9 (1.9%)
MOF 7 (1.8%) 5 (5.7%) 12 (2.5%)
Hemorrhage 4 (1%) 1 (1.1%) 5 (1.1%)
Failure/rejection 3 (0.8%) 3 (3.4%) 6 (1.3%)
IP 3 (0.8%) 1 (1.1%) 4 (0.8%)
Other second malignancy 3 (0.8%) 2 (2.3%) 5 (1.1%)
VOD 2 (0.5%) 1 (1.1%) 3 (0.6%)
Cardiac toxicity 1 (0.3%) 0 (0%) 1 (0.2%)
CNS toxicity 0 (0%) 4 (4.5%) 4 (0.8%)
Missing 10 3 13

CNS, central nervous system; IP, interstitial pneumonitis; MOF, multiorgan failure; VOD, veno-occlusive disease of the liver.